XTL Biopharmaceuticals Ltd. (XTLB) Key Metrics
XTLB valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $4.8M
- Enterprise value
- $6.0M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 5.8
- Price / book
- 1.9
- EV / EBITDA
- 16.9
- Dividend yield
- —
- Beta
- 0.42
XTLB key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsXTLB returns How much profit the business earns on the capital it uses.
XTLB financial health Debt, liquidity and how easily interest is covered.
XTLB returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
XTLB debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
XTLB key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Share price at fiscal year-end | $2.32 | $8.10 | $4.04 | $4.84 | $11.08 | $12.12 | $5.48 | $6.92 | $9.15 | $12.69 |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | — | −26.8% | −0.1% | −28.9% | 9.7% | −14.8% | −17.6% | 50.0% | −24.8% | −67.2% |
| Return on invested capital (ROIC) | — | −73.9% | −245.7% | — | — | — | −294.3% | — | — | −377.1% |
| Return on assets (ROA) | −159.9% | −18.7% | −0.1% | −25.0% | 6.6% | −11.4% | −17.1% | 39.4% | −16.3% | −61.0% |
| Return on tangible assets | — | −66.6% | −0.1% | −35.4% | 7.0% | −12.8% | −19.7% | 36.4% | −12.6% | −92.1% |
| Free cash flow margin | — | −370.7% | — | — | −71.6% | — | — | — | — | — |
| Income quality (OCF / net income) | — | — | — | — | −2.41 | — | — | −0.27 | — | — |
| Financial health | ||||||||||
| Total debt | $269,000 | $138,000 | — | — | — | — | — | — | — | — |
| Cash & short-term investments | $144,000 | $1.1M | $2.0M | $3.7M | $6.1M | $6.0M | $6.7M | $8.1M | $6.1M | $2.4M |
| Net debt | $125,000 | −$1.0M | −$2.0M | −$3.7M | −$6.1M | −$6.0M | −$6.7M | −$8.1M | −$6.1M | −$2.4M |
| Debt / equity | — | 0.03 | — | — | — | — | — | — | — | — |
| Debt / assets | 1.62 | 0.02 | — | — | — | — | — | — | — | — |
| Current ratio | 0.40 | 0.61 | 9.93 | 20.35 | 27.00 | 24.10 | 29.44 | 32.39 | 20.69 | 8.35 |
| Quick ratio | 0.40 | 0.61 | 10.07 | 20.35 | 27.00 | 24.10 | 29.44 | 32.48 | 20.40 | 7.95 |
| Interest coverage | -241.1 | -25.3 | -191.3 | -80.0 | -49.1 | -55.8 | -29.0 | -113.3 | -155.8 | -160.1 |
| Working capital | −$254,000 | −$867,000 | $1.8M | $3.6M | $6.0M | $5.9M | $6.6M | $7.9M | $5.9M | $2.4M |
| Invested capital | −$129,000 | $4.4M | $214,000 | $278,000 | −$794,000 | −$2.4M | $252,000 | $200,000 | −$2.5M | $254,000 |
| Tangible asset value | −$254,000 | −$1.6M | $1.8M | $3.6M | $5.0M | $5.9M | $6.6M | $7.9M | $3.2M | $2.4M |
| Net current asset value | −$254,000 | −$1.8M | $1.8M | $3.6M | $5.0M | $5.9M | $6.6M | $7.9M | $3.2M | $2.4M |
| Capital allocation | ||||||||||
| Share buybacks (net) | — | — | — | — | — | — | — | — | $0 | $0 |
| Capex / revenue | — | 12.0% | — | — | 0.0% | 3.6% | 2.9% | 3.8% | 6.9% | 287.0% |
| Capex / depreciation | — | 0.27 | 0.00 | 0.00 | 0.00 | 1.00 | 0.00 | 2.00 | 2.00 | 22.00 |
| Stock-based compensation / revenue | — | 58.5% | — | — | 2.5% | 182.1% | 7.2% | 46.2% | 137.9% | 791.3% |
| R&D / revenue | — | 21.7% | — | — | 2.0% | 135.7% | 50.7% | 73.1% | 148.3% | 1,926.1% |
| SG&A / revenue | — | 453.7% | — | — | 68.3% | 3,250.0% | 1,169.6% | 1,451.9% | 4,117.2% | 5,487.0% |
| Efficiency | ||||||||||
| Days sales outstanding | — | 51.8 | — | — | 23.4 | — | — | 119.3 | 151.0 | 380.9 |
| Days of inventory on hand | — | — | — | — | — | — | — | — | 39,237.5 | 9,368.3 |
| Days payables outstanding | — | 80.3 | — | 730.0 | 730.0 | 547.5 | — | — | 3,832.5 | 8,212.5 |
| Cash conversion cycle (days) | — | -28.5 | — | — | -706.6 | — | — | — | 35,556.0 | 1,536.7 |
| Receivables turnover | 0.00 | 7.05 | 0.00 | 0.00 | 15.60 | — | — | 3.06 | 2.42 | 0.96 |
| Payables turnover | 0.00 | 4.55 | 0.00 | 0.50 | 0.50 | 0.67 | 0.00 | 0.00 | 0.10 | 0.04 |
| Inventory turnover | — | — | — | — | — | — | — | — | 0.01 | 0.04 |
| Asset turnover | 0.00 | 0.08 | 0.00 | 0.00 | 0.22 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 |
| Average receivables | $49,500 | $64,000 | $50,000 | $82,500 | $94,000 | — | — | $17,000 | $12,000 | $24,000 |
| Average payables | $108,000 | $98,500 | $1,500 | $2,000 | $2,000 | $1,500 | $127,000 | $128,500 | $10,500 | $67,500 |
| Average inventory | — | — | −$29,000 | — | — | — | — | $31,500 | $107,500 | $77,000 |
| Intangibles / total assets | 0.0% | 82.0% | 15.7% | 9.1% | 5.7% | 5.8% | 5.3% | 4.4% | 5.8% | 8.4% |
Computed from XTLB's annual financial statements (latest annual report filed June 30, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
XTLB valuation and financial ratios
It ended the year with $0.3 million of debt and $0.1 million in cash and short-term investments, net debt of $0.1 million.
See the XTLB income statement, the XTLB chart for price history, or the XTLB stock overview for the latest quote and news.
XTLB key metrics FAQ
How much debt does XTL Biopharmaceuticals have?
XTL Biopharmaceuticals had total debt of $0.3 million at the end of fiscal 2025.
What is XTL Biopharmaceuticals's current ratio?
XTL Biopharmaceuticals's current ratio was 0.40 at the end of fiscal 2025: current assets were 0.40 times current liabilities.